Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-host-Disease

Summary

A Phase I Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease in patients who do not obtain complete remission with ruxolitinib

Timeline

Start

2018-09-25

Primary completion

2022-03-24

Completion

2022-03-24

Outcome

Results reported · no primary-endpoint met/missed verdict (typical of a dose-finding / safety study)

paper Although these studies were not powered to assess efficacy PMID 41637631 ↗

Publications

• Soares MVD, Gomez VE, Azevedo RI, Pereira PNG, Velazquez TC, Mendes L, Alho AC, Garcia-Guerrero E, Garcia-Calderon CB, Tharmaratnam K, Cabral IA, Ribeiro AC, Juncal C, Roncon S, Pais AT, Gil AR, Espada E, Rodrigues A, Garcao A, Yaspo ML, Warnatz HJ, Lehrach H, Ward L, Barbosa-Morais NL, Quintas AM, Palmela P, Caldas C, Ferreira R, Leite L, Martins C, Lourenco F, Moreno R, Campilho F, Cheyne CP, Garcia-Finana M, Campos A, Baron F, Arpinati M, Hoffmann P, Edinger M, Koreth J, Ritz J, Vaz CP, Perez-Simon JA, Lacerda JF. Phase 1/2 trials of donor regulatory T cells for the treatment of steroid-refractory chronic graft-versus-host disease. Blood Adv. 2026 May 12;10(9):2904-2915. doi: 10.1182/bloodadvances.2025017996.

Drugs

Indications